Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares

Cogent Biosciences, Inc. (NASDAQ:COGT) insider John Edward Robinson sold 90,000 shares of the firm’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.74, for a total transaction of $3,486,600.00. Following the sale, the insider owned 140,002 shares in the company, valued at approximately $5,423,677.48. This represents a 39.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Cogent Biosciences Price Performance

Shares of Cogent Biosciences stock traded down $0.80 during trading hours on Tuesday, reaching $37.12. The stock had a trading volume of 2,154,658 shares, compared to its average volume of 2,262,187. The stock’s 50 day moving average is $31.72 and its 200 day moving average is $18.82. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23. Cogent Biosciences, Inc. has a twelve month low of $3.72 and a twelve month high of $43.73. The firm has a market capitalization of $5.29 billion, a PE ratio of -22.63 and a beta of 0.49.

Cogent Biosciences (NASDAQ:COGT) last posted its earnings results on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. Equities analysts expect that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. increased its holdings in shares of Cogent Biosciences by 41.4% in the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after purchasing an additional 1,333 shares during the last quarter. Strs Ohio purchased a new stake in Cogent Biosciences in the 1st quarter valued at $36,000. Ameritas Investment Partners Inc. increased its stake in shares of Cogent Biosciences by 16.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company’s stock worth $78,000 after acquiring an additional 1,543 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Cogent Biosciences by 22.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock worth $78,000 after acquiring an additional 1,003 shares during the period. Finally, CWM LLC boosted its position in shares of Cogent Biosciences by 25.3% during the 3rd quarter. CWM LLC now owns 5,582 shares of the technology company’s stock valued at $80,000 after acquiring an additional 1,126 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on COGT. Raymond James Financial began coverage on Cogent Biosciences in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $30.00 target price for the company. Robert W. Baird boosted their target price on shares of Cogent Biosciences from $14.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Cogent Biosciences in a research report on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a report on Monday, December 8th. Finally, Wall Street Zen raised Cogent Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.82.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.